| 5 | 2/1 | 返回列表 |
| 查看: 5905 | 回復(fù): 30 | |||
| 當(dāng)前只顯示滿足指定條件的回帖,點(diǎn)擊這里查看本話題的所有回帖 | |||
F_Shaw捐助貴賓 (著名寫手)
|
[交流]
兩個審稿人給出了大改,但Associate Editor給了拒稿 已有3人參與
|
||
|
Dear Dr. XXXX, Reviewers' comments on your work have now been received. You will see that they are advising that we consider accepting your paper after major revision. However the needed revisions are too substantion to allow the paper to proceed without a second round of review. Please consider my rejection this version a "soft" decision. Both reviewers have indicated that they would like to see the revision and they will be invited to review the new submission. Both reviewers have agreed to be identified. XXXX is Reviewer #1, and XXXXX is Reivewer #2. Both reviewers have downloaded files in addition to the comments listed below. Let me know if you have any problems downloading this files. The one issue that must be addressed in a revision is a clear distinguition from previous publihsed papers. It is fine to document how new data supports conclusions made in prior work, but these must be significant advances and you must be clear as to why the new information either proves or disproves previous studies. Considering the extent of revision needed, I have not provided any editorial input to this version. I would be willing to help you with the revision prior to your formal resubmission. The easiest way to do this is for you to email me your revised manuscript (XXXXXXX) and we can work outside of the Elsevier system. ———————————————— Reviewer #1: The purpose of this paper, as poorly stated in lines 90-95,XXXXXX. I completely re-wrote this paper because without doing so, it would have been impossible to understand the aim of the work. Although the paper is very poorly written, it may be worthy of publication with major revisions. I have two major objections (items 1-2 below) and several recommendations for the authors. XXXXXXX ———————————————— Reviewer #2: The manuscript presented a valuable case study on XXXXX. XXXXXXXXXX. The data analysis is logical, the conclusions are convincing in general. The figures and tables are largely adequate to support the points made in the current manusript. The length of the manuscript is about right, although it could be slightly longer if the authors are going to make revisions according to the reviewer's suggestions. Major issues with the current manuscript include the following: XXXXXXXXX ______________________ 兩個審稿人提了很多意見,Associate Editor的意思是在我重投之前,可以協(xié)助我修改,工作量有點(diǎn)大啊! 各位蟲友有沒有這樣的經(jīng)歷,像這樣機(jī)會大不大? [ Last edited by F_Shaw on 2014-4-11 at 13:58 ] |

木蟲 (著名寫手)
![]() ![]() ![]() |
鐵桿木蟲 (知名作家)

| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 生物學(xué)調(diào)劑 +4 | Surekei 2026-03-21 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 化學(xué)調(diào)劑 +5 | yzysaa 2026-03-21 | 5/250 |
|
|
[考研] 考研化學(xué)學(xué)碩調(diào)劑,一志愿985 +5 | 張vvvv 2026-03-15 | 7/350 |
|
|
[考研] 297求調(diào)劑 +11 | 戲精丹丹丹 2026-03-17 | 12/600 |
|
|
[考研] 0805材料320求調(diào)劑 +3 | 深海物語 2026-03-20 | 3/150 |
|
|
[考研] 085700資源與環(huán)境308求調(diào)劑 +12 | 墨墨漠 2026-03-18 | 13/650 |
|
|
[考研] 材料 336 求調(diào)劑 +3 | An@. 2026-03-18 | 4/200 |
|
|
[考研] 華東師范大學(xué)-071000生物學(xué)-293分-求調(diào)劑 +3 | 研究生何瑤明 2026-03-18 | 3/150 |
|
|
[考研] 304求調(diào)劑 +6 | 曼殊2266 2026-03-18 | 6/300 |
|
|
[考研] 材料專業(yè)求調(diào)劑 +6 | hanamiko 2026-03-18 | 6/300 |
|
|
[考研] 296求調(diào)劑 +6 | www_q 2026-03-18 | 10/500 |
|
|
[考研] 藥學(xué)383 求調(diào)劑 +3 | 藥學(xué)chy 2026-03-15 | 5/250 |
|
|
[考研] 北科281學(xué)碩材料求調(diào)劑 +5 | tcxiaoxx 2026-03-20 | 5/250 |
|
|
[考研] 一志愿西安交通大學(xué) 學(xué)碩 354求調(diào)劑211或者雙一流 +3 | 我想要讀研究生 2026-03-20 | 3/150 |
|
|
[考研] 工科材料085601 279求調(diào)劑 +7 | 困于星晨 2026-03-17 | 9/450 |
|
|
[考研] 328求調(diào)劑,英語六級551,有科研經(jīng)歷 +4 | 生物工程調(diào)劑 2026-03-16 | 12/600 |
|
|
[考研] 【同濟(jì)軟件】軟件(085405)考研求調(diào)劑 +3 | 2026eternal 2026-03-18 | 3/150 |
|
|
[考研] 0854可跨調(diào)劑,一作一項核心論文五項專利,省、國級證書40+數(shù)一英一287 +8 | 小李0854 2026-03-16 | 8/400 |
|
|
[考研] 考研求調(diào)劑 +3 | 橘頌. 2026-03-17 | 4/200 |
|
|
[碩博家園] 湖北工業(yè)大學(xué) 生命科學(xué)與健康學(xué)院-課題組招收2026級食品/生物方向碩士 +3 | 1喜春8 2026-03-17 | 5/250 |
|